- Home
- PANW vs AMGN Comparison
PANW vs AMGN Comparison
Compare PANW & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | AMGN |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.5B | 188.7B |
| IPO Year | 2012 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PANW | AMGN |
|---|---|---|
| Price | $301.85 | $355.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 39 | 19 |
| Target Price | $216.28 | ★ $351.05 |
| AVG Volume (30 Days) | ★ 8.0M | 2.9M |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.98% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | 0.79 | ★ 3.34 |
| Revenue | $2,273,100,000.00 | ★ $25,424,000,000.00 |
| Revenue This Year | $24.93 | $5.00 |
| Revenue Next Year | $19.97 | $2.45 |
| P/E Ratio | $370.17 | ★ $105.51 |
| Revenue Growth | ★ 29.04 | 8.83 |
| 52 Week Low | $139.57 | $269.77 |
| 52 Week High | $302.95 | $391.29 |
Technical Indicators
Market Signals| Indicator | PANW | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.57 | 60.70 |
| Support Level | $179.81 | $334.72 |
| Resistance Level | $302.95 | $357.01 |
| Average True Range (ATR) | 11.33 | 8.88 |
| MACD | -0.85 | 1.00 |
| Stochastic Oscillator | 99.51 | 79.77 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.